Rallybio has commenced an open-label Phase II trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunisation ...

ImmunityBio has partnered with nCartes to automate and expedite the data fulfilment process for clinical trials.

Dubbed Nubeqa but known generically as darolutamide, the treatment comes in combination with androgen deprivation therapy ...

The consortium aims to attract global pharma and medical device companies for clinical trial research investment in Israel.

Endeavor has dosed the first subject in the randomised Phase IIb WHISTLE-PF trial of ENV-101 (taladegib) for IPF.

The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.

The company’s VP of digital excellence explains how the Japanese biotech engages with data and uses it to inform decision ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...

Puma Biotechnology has commenced the Phase II trial, ALISCA-Breast1, to evaluate oral alisertib, a selective inhibitor of ...

Emmecell has published positive topline outcomes from a Phase I trial of EO2002, its nonsurgical cell therapy candidate for ...

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.